Armin Wolf
Armin Wolf is an expert in Ophthalmology at University Hospital Ulm (Germany). As of October 2026, ScienceLeadR ranks Armin Wolf in the top 1% of experts worldwide for Retinal Diseases. Armin Wolf has authored 452 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 10 of them ongoing. SLR score: 1,441 (community average: 125). How the SLR is computed.
LeadR Profile
Ophthalmology
Subspecialties: Pharmacy - Public Health - Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1989 - 2026
Number : 452
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Diabetic cataract at type 1 diabetes onset: frequency and characteristics. PMID 42867837 — diabetes mellitus, metabolic diseases, hyperglycemia, adolescent, prevalence, visual acuity, cataract, diabetes mellitus, type 1, child | J Pediatr Endocrinol Metab | 2026 | 0 |
| Retinal glial cell removing during internal limiting membrane peeling is associated with higher-stage idiopathic epiretinal membrane. PMID 42844643 — eye, cells, neuroglia, tomography, optical coherence, tissues, retinaldehyde, membranes, epiretinal membrane | Eye Vis (Lond) | 2026 | 0 |
| Oral belzutifan treatment in von hippel-lindau-associated retinal hemangioblastoma: a promising approach. PMID 42745329 — eye, research design, hemangioblastoma, therapeutics, retinaldehyde, wounds and injuries | Int J Retina Vitreous | 2026 | 0 |
| Infants with retinopathy of prematurity (ROP) in Germany and Türkiye-a comparison based on data from the EU-ROP registry. PMID 42592060 — registries, eye, laser coagulation, bevacizumab, ranibizumab, lasers, retreatment, retinopathy of prematurity, therapeutics, demography, child, infant | Front Med (Lausanne) | 2026 | 0 |
| Kahook Dual Blade: six-month results in uncontrolled open angle glaucoma. PMID 42523571 — glaucoma, open-angle, glaucoma, intraocular pressure, trabeculectomy | Int J Ophthalmol | 2026 | 0 |
Clinical Studies 20
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
10 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study to Assess the Injection Burden Safety Efficacy and Long Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV RGX 314) Compared to Ranibizumab in Adult Participants with Neovascular Age Related Macular Degeneration (nAMD) 2024-512298-28-00 — injections, macular degeneration, safety, ranibizumab, visual acuity | Phase 3/Phase 4 | Recruiting | 2025 |
| A study to test whether BI 764524 helps people with an eye condition called diabetic retinopathy 2023-508891-12-00 — eye, safety, diabetic retinopathy, pharmacokinetics | Phase 2 | Active not recruiting | 2024 |
| A Study of the Efficacy Safety and Pharmacokinetics of A 36 Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients with Wet Age Related Macular Degeneration (Velodrome) 2023-507130-24-00 — macular degeneration, safety, ranibizumab, pharmacokinetics | Phase 3 | Active not recruiting | 2021 |
| Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy NCT07531927 — eye, pilot projects, macular degeneration, pilots, safety, atrophy, retina, electrodes, therapeutics, retinaldehyde, geographic atrophy | N/A | Recruiting | 2026 |
| A Study to Determine Safety and Long Term Effectiveness of Faricimab in Participants with Age Related Macular Degeneration 2024-517545-13-00 — macular degeneration, safety | Phase 3/Phase 4 | Active not recruiting | 2025 |
LeadR Networks
Main global connection map